Results 121 to 130 of about 42,681 (176)

Overexpression of oncogenic polo-like kinase 1 disrupts the invasiveness, cell cycle, and apoptosis in synovial sarcoma. [PDF]

J Transl Med
Zhang J, Li Z, Xie MY, Wang N, Liu H, Li F, Pang LJ, Qi Y.   +7 more
europepmc   +1 more source

Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells. [PDF]

J Breast Cancer, 2022
Quan M, Oh Y, Cho SY, Kim JH, Moon HG.
europepmc   +1 more source

Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study. [PDF]

Biomedicines
Jajac Brucic L, Bisof V, Soce M, Skelin M, Krecak I, Nadinic A, Vrbicic B, Puljiz Z, Hancic S, Gasparov S.   +9 more
europepmc   +1 more source

Identification of potential functions of polo-like kinase 1 in male reproductive development of the oriental river prawn (Macrobrachium nipponense) by RNA interference analysis. [PDF]

Front Endocrinol (Lausanne), 2022
Jin S, Zhang W, Wang P, Jiang S, Qiao H, Gong Y, Wu Y, Xiong Y, Fu H.   +8 more
europepmc   +1 more source

Targeting polo-like kinase 1 in pediatric leukemia

, 2020
Acute lymphoblastic leukemia (ALL) is one of the most common cancers among children in the world, with almost 90% complete remission rate after the primary treatment. However, some patients are resistant to treatment and some relapse later. Moreover, existing treatments are toxic and induce life-long adverse effects. Potentially, it can be avoided if a
openaire   +1 more source

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. [PDF]

Mol Cancer Ther
Nouri M, Varkaris A, Ridinger M, Dalrymple SL, Dennehy CM, Isaacs JT, Einstein DJ, Brennen WN, Balk SP.   +8 more
europepmc   +1 more source

Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: A systematic review and meta-analysis. [PDF]

Front Oncol, 2022
Wang MW, Li Z, Chen LH, Wang N, Hu JM, Du J, Pang LJ, Qi Y.   +7 more
europepmc   +1 more source

Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib. [PDF]

Int J Mol Sci
Fischer J, Erkner E, Radszuweit P, Hentrich T, Keppeler H, Korkmaz F, Schulze-Hentrich J, Fitzel R, Lengerke C, Schneidawind D, Schneidawind C.   +10 more
europepmc   +1 more source

Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer. [PDF]

Cancers (Basel)
Zhang G, Pannucci A, Ivanov AA, Switchenko J, Sun SY, Sica GL, Liu Z, Huang Y, Schmitz JC, Owonikoko TK.   +9 more
europepmc   +1 more source

MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer. [PDF]

Cancer Res Commun
Williams I, O'Malley M, DeHart H, Walker B, Ulhaskumar V, Jothirajah P, Ray H, Landrum LM, Delaney JR, Nephew KP, Carpenter RL.   +10 more
europepmc   +1 more source